SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

Company launches multi-channel promotional campaignto drive market adoption

U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension

COMMACK, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced the start of commercial sales and fulfillment of the first customer orders for Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL, marking an important milestone in the Company’s growth as it begins to bring this differentiated product to market.

Arbli™ is the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium, designed to provide a safe, consistent, and convenient therapeutic option for patients requiring an alternative to solid dosage forms. According to IQVIA data (MAT June 2025), the U.S. losartan market totals approximately $256 million in annual sales, with more than 71 million prescriptions written each year, presenting a significant commercial opportunity for Scienture and its distribution partners.

As part of its commercial campaign, Scienture is executing targeted outreach for Arbli™ to healthcare professionals (HCPs) and has finalized PBM-Led GPO agreements for expanded commercial coverage and formulary access. In addition, Scienture has also formalized multiple commercial group purchasing organization (GPO) agreements, expanding Arbli’s market access to over 2,500 healthcare institutions nationwide. This includes hospitals, clinics, nursing homes, specialty pharmacies, long-term care facilities, and ambulatory centers, collectively representing potential penetration into an estimated 20% of the U.S. institutional market. The agreements also establish a broad footprint across long-term care and outpatient facilities, strengthening the company’s commercial reach.

“The start of commercial sales for Arbli™ represents a major achievement for Scienture as we transition from development to execution,” commented Narasimhan Mani, President and co-CEO of Scienture. “As promotional efforts expand and demand builds across retail, institutional and long-term care markets, we see significant potential for sustained adoption and value creation.”

“Arbli™ embodies our mission to deliver patient-focused pharmaceutical solutions that improve access and convenience,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “We are encouraged by the early response from healthcare institutions and remain committed to expanding education, awareness, and availability of this first-of-its-kind treatment option.”

About Arbli™

Arbli™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.

Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.

INDICATION

Arbli™ is an angiotensin II receptor blocker (ARB) indicated for:

Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.

IMPORTANT SAFETY INFORMATION

Do not take Arbli™when pregnant. When pregnancy is detected, discontinue Arbli™as soon as possible.Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Do not co-administer Arbli™ with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli™ in patients with renal impairment (GFR